logo
logo
Sign in

Denosumab Global Market 2024 - By Size, Demand, Share, Trends, Forecast To 2033

avatar
varun@tbrc
Denosumab Global Market 2024 - By Size, Demand, Share, Trends, Forecast To 2033

The Denosumab Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).


Learn More On The Denosumab Market:

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report


According to The Business Research Company’s Denosumab Global Market Report 2024, The denosumab market size is expected to see rapid growth in the next few years. It will grow to $5.06 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to rising incidence of bone metastases, advancements in cancer therapies, osteoporosis prevalence, increased awareness of osteoporosis, regulatory approvals for new indications. Major trends in the forecast period include strategic collaborations and partnerships, integration with digital health solutions, expanded indications and clinical applications, advancements in biosimilar development.


The increasing prevalence of osteoporosis is expected to propel the growth of the denosumab market going forward. Osteoporosis is a medical condition where the bones become weak, resulting in lower bone density and a higher risk of fractures. Denosumab is used to treat osteoporosis by stopping bone resorption through the targeting of the RANK ligand. For instance, In December 2023, according to a report published by the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, osteoporosis contributed to 2,366 deaths, or 6.5 deaths per 100,000 population in 2021, representing 1.4% of all deaths. Further, in 2021–22, there were 9,500 hospitalizations with a principal diagnosis of osteoporosis (89 hospitalizations per 100,000 population) for people aged 45 and over. Therefore, the increasing prevalence of osteoporosis is driving the growth of the denosumab market.


Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp


The denosumab market covered in this report is segmented –

1) By Drug Classification: Prolia, Xgeva, Others

2) By Type: 60 mg, 120 mg

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers


Major companies operating in the denosumab market are increasing their focus on introducing innovative solutions, such as first-line treatments for osteoporosis, to gain a competitive edge in the market. First-line treatment for osteoporosis refers to the initial or primary therapeutic approach recommended by healthcare professionals when managing individuals diagnosed with osteoporosis. For instance, in November 2022, Boan Biotech, a China-based biotechnology company, received approval from China's National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, making it the first Chinese company to develop a denosumab injection. It is also being developed for markets outside of China, including Europe and the United States, with plans for global marketing. The drug has been recommended as a first-line treatment for osteoporosis in various treatment guidelines. The medication has the potential to dramatically lower the risk of hip, non-vertebral, and vertebral fractures in this patient population. Additionally, Boyoubei is the first biosimilar to Prolia (the originator of denosumab) approved for marketing in the world.


The denosumab market report table of contents includes:

1. Executive Summary

2. Denosumab Market Characteristics

3. Denosumab Market Trends And Strategies

4. Denosumab Market - Macro Economic Scenario

5. Global Denosumab Market Size and Growth

.................

31. Denosumab Market Other Major And Innovative Companies

32. Global Denosumab Market Competitive Benchmarking

33. Global Denosumab Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Denosumab Market

35. Denosumab Market Future Outlook and Potential Analysis


Read Related Topics:

https://goodprnews.com/tankless-water-heater-global-market-size/

https://goodprnews.com/topical-pain-relief-global-market-size/

https://goodprnews.com/skin-packaging-global-market-size/

https://topprnews.com/tankless-water-heater-global-market-share/

https://topprnews.com/topical-pain-relief-global-market-share/

https://topprnews.com/skin-packaging-global-market-share/


Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [email protected]


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

collect
0
avatar
varun@tbrc
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more